Abstract: Disclosed herein are novel diagnostic lung cancer panels and the use of these panels to diagnose, predict, and characterize lung cancer and to monitor or predict treatment efficacy.

Abstract: The invention is a novel scheme of performing an analog to digital conversion of simultaneous sampled analog inputs using multiple sample and hold circuits and a single successive approximation analog to digital converter (“SAR ADC”). Each of the analog inputs are stored on capacitors in the sample and hold circuits, and the sample and holds are sequentially connected to the capacitor DAC. After the digital conversion of the of the input signals stored on a sample and hold, the connected sample and hold is disconnected and the charge on the DAC is reset before the next sample and hold circuit is connected. The process is repeated until all analog inputs have been converted.

Abstract: A fail-safe system is provided for an autonomous vehicle. The vehicle has a source of electrical power and electrical loads. The fail-safe system includes an operator controlled remote unit, a wireless transmitter connected to the remote unit for transmitting a wireless keep alive signal, a wireless receiver mounted on the vehicle for receiving the keep alive signal and a fail-safe unit connected to the receiver. The fail-safe unit includes first and second processing units, both connected to each other, to the receiver and to relay units which are operable to connect and disconnect the source of electrical power from the electrical loads in response to a signal from one of the processing units. Both processing units are operable to open their respective relay units and shut down all vehicle operations in response to a variety of fault conditions, including loss of the keep alive signal from the remote unit.

Abstract: The invention is a novel scheme of performing an analog to digital conversion of simultaneous sampled analog inputs using multiple sample and hold circuits and a single successive approximation analog to digital converter (“SAR ADC”). Each of the analog inputs are stored on capacitors in the sample and hold circuits, and the sample and holds are sequentially connected to the capacitor DAC. After the digital conversion of the of the input signals stored on a sample and hold, the connected sample and hold is disconnected and the charge on the DAC is reset before the next sample and hold circuit is connected. The process is repeated until all analog inputs have been converted.

Abstract: The invention relates to an electric power supply system for a by-wire vehicle system. There is a need for a power supply system which allows the integrity of the battery and alternator to be monitored. A vehicle electric power supply system includes a battery, an alternator, a key operated switch and at least two electronic control units (ECUs). A battery line is connected to the battery, to the second ECU, and to the key switch. An alternator line connects the alternator to the first ECU and to the key switch. A relay includes a relay switch which opens and closes a connection between the battery line and the alternator line. A relay coil is energizable to cause the relay switch to connect the battery line to the alternator line. Energization of the relay coil is controlled by one of the ECUs. This ECU causes the relay coil to move the switch element disconnect the alternator line from the battery line so that voltage from the alternator and battery can be independently tested.

Abstract: The invention relates to an electrical system or circuit for a by-wire control system. The control system includes a hydraulic pump, a reservoir, a bi-directional function actuator, and solenoid operated valves for controlling the actuator in response to control signals from the electronic system. The electronic system includes first and second pairs of command device position sensors, a first channel and a second channel. Each channel includes main processing unit and a supervisory control unit. Each main processing unit is connected to a pair of the command device position sensors, and a pair of the solenoid operated valves.

Abstract: Surprisingly, the present inventors have discovered that expression of TAT-041 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-041 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-041 expression or activity, comprising: contacting a candidate compound with a TAT-041 and detecting the presence or absence of binding between said compound and said TAT-041, or detecting a change in TAT-041 expression or activity. Methods are also included for the identification of compounds that modulate TAT-041 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-041 expression or activity.

Abstract: Systems, methods, apparatus, and computer programming useful in identifying proteins, peptides, carbohydrates, and other biomolecules, or for a validation of an identification of proteins, peptides, carbohydrates, and other biomolecules, is described. In particular, the invention provides systems, methods, apparatus, and programming useful for identifying proteins and other precursor biomolecules using expression patterns associated with peptides or other biomolecule fragments expressed from analyte samples, and data representing such expression patterns, and for determining and improving confidence levels associated with identification of precursor biomolecules using such methods, through the correlation of expression patterns for fragments associated with precursor biomolecules.

Abstract: Surprisingly, the present inventors have discovered that expression of TAT-046 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-046 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-046 expression or activity, comprising: contacting a candidate compound with a TAT-046 and detecting the presence or absence of binding between said compound and said TAT-046, or detecting a change in TAT-046 expression or activity. Methods are also included for the identification of compounds that modulate TAT-046 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-046 expression or activity.

Abstract: Surprisingly, the present inventors have discovered that expression of TAT-042 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-042 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-042 expression or activity, comprising: contacting a candidate compound with a TAT-042 and detecting the presence or absence of binding between said compound and said TAT-042, or detecting a change in TAT-042 expression or activity. Methods are also included for the identification of compounds that modulate TAT-042 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-042 expression or activity.

Abstract: Surprisingly, the present inventors have discovered that expression of TAT-039 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-039 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-039 expression or activity, comprising: contacting a candidate compound with a TAT-039 and detecting the presence or absence of binding between said compound and said TAT-039, or detecting a change in TAT-039 expression or activity. Methods are also included for the identification of compounds that modulate TAT-039 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-039 expression or activity.

Abstract: Surprisingly, the present inventors have discovered that expression of TAT-028 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-028 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-028 expression or activity, comprising: contacting a candidate compound with a TAT-028 and detecting the presence or absence of binding between said compound and said TAT-028, or detecting a change in TAT-028 expression or activity. Methods are also included for the identification of compounds that modulate TAT-028 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-028 expression or activity.

Abstract: Surprisingly, the present inventors have discovered that expression of TAT-038 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-038 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-038 expression or activity, comprising: contacting a candidate compound with a TAT-038 and detecting the presence or absence of binding between said compound and said TAT-038, or detecting a change in TAT-038 expression or activity. Methods are also included for the identification of compounds that modulate TAT-038 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-038 expression or activity.

Abstract: Surprisingly, the present inventors have discovered that expression of TAT-044 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-044 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-044 expression or activity, comprising: contacting a candidate compound with a TAT-044 and detecting the presence or absence of binding between said compound and said TAT-044, or detecting a change in TAT-044 expression or activity. Methods are also included for the identification of compounds that modulate TAT-044 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-044 expression or activity.

Abstract: Before a transaction takes place between a plurality of agent-based devices (21-29), not all of which have previous experience of each other, a data file is created which identifies all the agents which are to take part in the transaction. The data file is circulated to all the agents, and each agent endorses the data file in respect of each other agent with a positive, negative, or conditional endorsement, based on stored data indicating whether that agent is capable of co-operation with the other agent. A negative endorsement is applied by an agent in respect of any agent with which it is not prepared to co-operate. Such a negative endorsement is fatal to the transaction. A positive endorsement is applied by an agent (21) in respect of any other agent (27) with which it is unconditionally prepared to co-operate.

Abstract: An identity confirmation device comprises a token issuer 4 and an authentication device 5, the token issuer being programmable by a central identity provider 2 to issue certification tokens for use in e-commerce whereby transactions can be certified with suppliers without need for additional communication with a central server.

Abstract: Surprisingly, the present inventors have discovered that expression of TAT-030 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-030 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-030 expression or activity, comprising: contacting a candidate compound with a TAT-030 and detecting the presence or absence of binding between said compound and said TAT-030, or detecting a change in TAT-030 expression or activity. Methods are also included for the identification of compounds that modulate TAT-030 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-030 expression or activity.

Abstract: Surprisingly, the present inventors have discovered that expression of TAT-036 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-036 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-036 expression or activity, comprising: contacting a candidate compound with a TAT-036 and detecting the presence or absence of binding between said compound and said TAT-036, or detecting a change in TAT-036 expression or activity. Methods are also included for the identification of compounds that modulate TAT-036 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-036 expression or activity.

Abstract: Surprisingly, the present inventors have discovered that expression of TAT-031 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-031 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-031 expression or activity, comprising: contacting a candidate compound with a TAT-031 and detecting the presence or absence of binding between said compound and said TAT-031, or detecting a change in TAT-031 expression or activity. Methods are also included for the identification of compounds that modulate TAT-031 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-031 expression or activity.

Abstract: Surprisingly, the present inventors have discovered that expression of TAT-001 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-001 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-001 expression or activity, comprising: contacting a candidate compound with a TAT-001 and detecting the presence or absence of binding between said compound and said TAT-001, or detecting a change in TAT-001 expression or activity.